亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group.

医学 乳腺癌 癌症 肿瘤科 转移性乳腺癌 内科学
作者
Gabriel N. Hortobágyi,Richard L. Theriault,A. Lipton,L Porter,Douglas W. Blayney,Clive Sinoff,Helen T. Wheeler,Joseph F. Simeone,John J. Seaman,Robert Knight,M Heffernan,Kathleen Mellars,Dirk J. Reitsma
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:16 (6): 2038-2044 被引量:659
标识
DOI:10.1200/jco.1998.16.6.2038
摘要

PURPOSE: Pamidronate, an aminobisphosphonate, has been shown to lower the risk of skeletal complications associated with lytic bone lesions for up to 1 year in women with stage IV breast cancer who received chemotherapy. We studied the long-term effectiveness and safety of continued treatment with intravenous pamidronate infusions for up to 2 years. PATIENTS AND METHODS: Three hundred eighty-two women with metastatic breast cancer and lytic bone lesions who received chemotherapy were randomly assigned to receive either 90 mg of pamidronate or placebo intravenously every 3 to 4 weeks in this double-blind, multicenter, parallel-group trial. Patients were evaluated monthly for 2 years for skeletal complications, which included pathologic fractures, need for radiation or surgery to treat bone complications, spinal cord compression, and hypercalcemia. Bone pain, analgesic use, bone biochemical markers, performance status, quality of life, radiologic response in bone, and survival were also evaluated. RESULTS: As in the first year of treatment, the proportion of patients with any skeletal complication was significantly less for the pamidronate than the placebo group at 15, 18, 21, and 24 months (P < .001). The proportions of patients with any pathologic fracture (i.e., vertebral and nonvertebral fractures), need for radiation or surgery to treat bone complications, and hypercalcemia were also statistically less for the pamidronate than the placebo group. The median time to the first skeletal complication was 13.9 months in the pamidronate-treated women and 7.0 months in the placebo group (P < .001). Long-term treatment did not result in any unexpected adverse events. Survival did not differ between the two groups. CONCLUSION: The risk for osteolytic bone lesion complications in metastatic breast cancer was significantly decreased with monthly infusions of 90 mg of pamidronate, and this effect was maintained for at least 2 years. Pamidronate is a useful adjunct to standard chemotherapy in the palliative treatment of metastatic breast cancer.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
159357发布了新的文献求助30
3秒前
可爱馒头完成签到,获得积分10
3秒前
3秒前
5秒前
传奇3的应助被Flynn采纳,获得10
6秒前
yangzai完成签到 ,获得积分0
7秒前
8秒前
李华完成签到,获得积分10
9秒前
9秒前
欣喜的若山完成签到 ,获得积分10
9秒前
黄天完成签到 ,获得积分10
10秒前
小叶子完成签到 ,获得积分10
11秒前
llqq完成签到,获得积分10
11秒前
洪亮完成签到,获得积分10
12秒前
李华发布了新的文献求助10
13秒前
14秒前
14秒前
14秒前
林诗萍完成签到 ,获得积分10
15秒前
Flynn发布了新的文献求助10
19秒前
清汐完成签到 ,获得积分10
19秒前
阿腾发布了新的文献求助10
20秒前
24秒前
loii的应助被务实的小凡采纳,获得50
24秒前
小马甲的应助被阿腾采纳,获得10
25秒前
27秒前
27秒前
Flynn完成签到,获得积分10
28秒前
陈鑫龙完成签到 ,获得积分10
28秒前
29秒前
liugaoleng完成签到 ,获得积分10
31秒前
31秒前
32秒前
巨型肥猫发布了新的文献求助10
32秒前
111发布了新的文献求助10
33秒前
瑩火虫完成签到 ,获得积分10
34秒前
Saturday完成签到,获得积分10
35秒前
tt完成签到 ,获得积分10
36秒前
36秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179656
求助须知:如何正确求助?哪些是违规求助? 9569921
关于积分的说明 21807706
捐赠科研通 7775141
什么是DOI,文献DOI怎么找? 3433072
关于科研通互助平台的介绍 2557032
邀请新用户注册赠送积分活动 2478778